Asthma Drug May Help Those With Long-Lasting Hives
Xolair found safe, effective for reducing symptoms, study finds
By Alan Mozes
MONDAY, July 21, 2014 (HealthDay News) -- A drug already used to treat moderate-to-severe allergic asthma appears to offer relief to people with chronic hives who haven't been helped by standard medications, new research suggests.
The prescription drug -- omalizumab (Xolair) -- is already available to treat hives, following U.S. Food and Drug Administration approval earlier this year for that use.
The current study confirms that when Xolair is taken at a high dose for a six-month period it seems to be both safe and effective at controlling the severe and often debilitating itching that characterizes long-term hives.
"So what we're talking about here are only chronic cases, in which patients have hives that last for more than six weeks," explained study senior author Dr. Karin Rosen, an associate group medical director with Genentech Inc., in San Francisco. "That's usually just .5 to 1 percent of hives patients."
"But for those patients, this is a really horrible disease," she noted. "And until now antihistamines have been the only approved drug for chronic hives. But to work, antihistamines often need to be used at up to four times approved levels, which has a sedating effect. And 50 percent of the time patients didn't respond anyway."
"So then," said Rosen, "they would try other types of medications, like systemic steroids. But over time steroids can have very severe side effects. So then we would turn to the heavy artillery, like [the immunosuppressant drug] cyclosporine, which also has very severe side effects, and can't be taken by people with high blood pressure or heart disease."
"All this means that many, many patients have simply been left without any treatment," she noted. "But with this drug we are seeing great improvement in patients who previously had no options. And that's very, very encouraging."
Rosen and her colleagues discuss their findings in the July 21 issue of the Journal of Investigative Dermatology. The current study is the latest in a series of ongoing studies, which are being funded by drug manufacturer Genentech Inc. and Novartis Pharma AG in Basel Switzerland.